home.aspx
 
EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...

Biocon

SHARESHARESHARE
Biocon Ltd. is India’s premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Established in 1978 by Ms Kiran Mazumdar-Shaw, Biocon is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases.
SHARESHARESHARE

RELATED NEWS


Biotechnology major Biocon and drug firm Mylan NV on Monday announced the launch of biosimilar Ogivri, used for treatment of certain breast and gastric cancers, in the US market.   Ogivri is available in a 420 mg multi-dose vial and a 150 mg single-dose vial in order to provide the patients dosing and treatment flexibility, the companies said in a joint statement.  "The US launch of Ogivri, the biosimilar trastuzumab co-developed by Biocon Biologics and Mylan, marks a signifi...

READ MORE

Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient in Sanofi’s Lantus blockbuster – have been dealt a blow. The FDA has issued a second complete response letter (CRL) rejecting the marketing application for the biosimilar after uncovering quality problems at Biocon – Mylan’s partner for the drug – in a pre-approval inspection of one of its manufacturing facilities in Malaysia. Biocon played down the implic...

READ MORE

Goodwin Biotechnology, Inc. ("Goodwin") announced that it has completed its largest ever round of financing with growth capital which will help fund its next stage of expansion.  Goodwin is a full GMP, FDA-registered biopharmaceuticals Contract Development and Manufacturing Organization (CDMO) that offers a fully integrated Single Source Solution™ from Cell Line Development, Process Development including Bioconjugation, Scale-Up, cGMP Contract Manufacturing and Aseptic Fill/...

READ MORE

Chennai: Fluctuating US Dollar has pushed prices of insulin pens, cartridges, and basal insulin by up to 20% over the last few months, thereby pushing up medical bills of diabetics in India. Diabetologists say nearly a third of-of their insulin dependent patients are now paying more for their daily medication. Data sourced from the online medical store, Netmeds, show that cost of basal insulin — the type of insulin that regulates glucose levels between meals preventing low sugar, and premi...

READ MORE

As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla. The Swiss pharma firm has announced that it has submitted a supplemental Biologics License Application to the US FDA that could broaden the drug’s use to the post-surgical treatment of people with HER2-positive early breast cancer, who still had signs of disease after they were treated before surgery. Kadcyla (trastuzumab emtansine) is ...

READ MORE

Sanofi’s Lantus is already facing off against generic competition from Eli Lilly and Boehringer’s Basaglar, but now Mylan is adding to the pressure by prevailing in a patent challenge at the U.S. Patent and Trademark Office. The PTO’s Patent Trial and Appeal Board invalidated two Lantus formulation patents, knocking down one barrier to market for Mylan and its partner Biocon as their generic awaits a decision at the FDA. The partners still face a patent fight with Sanofi in cou...

READ MORE

Cello’s US health consulting business Defined Health has been rebranded as Cello Health BioConsulting, following its acquisition by the group last year. Cello said the move was prompted by industry evolution and outlined how even the most scientifically-driven biotech companies need to think commercially sooner. Jon Bircher, CEO of Cello Health Consulting, said: “Since Defined Health joined the Cello Health family 18 months ago, we have spent significant time with our colleagues...

READ MORE

Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products, and will have a cost and profit share arrangemen...

READ MORE

Mylan and Biocon’s Ogivri is the first biosimilar of Herceptin to win US approval, for certain breast cancer and metastatic stomach cancers. The US Food and Drug Administration has cleared the drug’s use for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene....

READ MORE

Chasing biosim partners Mylan and Biocon for one of the top sales targets in the pharma industry, Celltrion reported Sunday that its version of Roche’s breast cancer med Herceptin stacked up to the reference blockbuster in a late-stage trial....

READ MORE

EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...